BRAF and metastatic melanoma: This led to the regulatory approval of vemurafenib, dabrafenib and encorafenib (and combinations with MEK inhibitors and other agents) for the treatment of patients with unresectable or metastatic melanoma harboring a BRAF V600E mutation [11–16].